+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Lower Back Pain (CLBP) - Market Insight, Epidemiology and Market Forecast -2032

  • ID: 4793085
  • Report
  • January 2022
  • Region: Global
  • 293 Pages
  • DelveInsight

FEATURED COMPANIES

  • Allodynic Therapeutics
  • Braeburn Inc.
  • DiscGenics Inc.
  • Frontier Biotechnologies
  • Persica Pharmaceuticals
  • Scilex Holding
This "Chronic Lower Back Pain (CLBP)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Lower Back Pain (CLBP), historical and forecasted epidemiology as well as the Chronic Lower Back Pain (CLBP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Lower Back Pain (CLBP) market report provides current treatment practices, emerging drugs, Chronic Lower Back Pain (CLBP) market share of the individual therapies, current and forecasted Chronic Lower Back Pain (CLBP) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chronic Lower Back Pain (CLBP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Chronic Lower Back Pain (CLBP) Disease Understanding and Treatment Algorithm


The Chronic Lower Back Pain (CLBP) market report gives a thorough understanding of the Chronic Lower Back Pain (CLBP) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Chronic Lower Back Pain (CLBP).

Treatment


It covers the details of conventional and current medical therapies available in the Chronic Lower Back Pain (CLBP) market for the treatment of the condition. It also provides Chronic Lower Back Pain (CLBP) treatment algorithms and guidelines in the United States, Europe, and Japan.

Chronic Lower Back Pain (CLBP) Epidemiology


The Chronic Lower Back Pain (CLBP) epidemiology division provide insights about historical and current Chronic Lower Back Pain (CLBP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Chronic Lower Back Pain (CLBP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Chronic Lower Back Pain (CLBP) Epidemiology


The epidemiology segment also provides the Chronic Lower Back Pain (CLBP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Lower Back Pain (CLBP) Drug Chapters


Drug chapter segment of the Chronic Lower Back Pain (CLBP) report encloses the detailed analysis of Chronic Lower Back Pain (CLBP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Lower Back Pain (CLBP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Chronic Lower Back Pain (CLBP) treatment.

Chronic Lower Back Pain (CLBP) Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Chronic Lower Back Pain (CLBP) treatment.

Chronic Lower Back Pain (CLBP) Market Outlook


The Chronic Lower Back Pain (CLBP) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Lower Back Pain (CLBP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Lower Back Pain (CLBP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Chronic Lower Back Pain (CLBP) market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Chronic Lower Back Pain (CLBP) market in 7MM.

The United States Market Outlook


This section provides the total Chronic Lower Back Pain (CLBP) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Chronic Lower Back Pain (CLBP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Chronic Lower Back Pain (CLBP) market size and market size by therapies in Japan is also mentioned.

Chronic Lower Back Pain (CLBP) Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain (CLBP) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Lower Back Pain (CLBP) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Lower Back Pain (CLBP) Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Lower Back Pain (CLBP) key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Lower Back Pain (CLBP) emerging therapies.

Reimbursement Scenario in Chronic Lower Back Pain (CLBP)


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Lower Back Pain (CLBP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Lower Back Pain (CLBP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Chronic Lower Back Pain (CLBP) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Lower Back Pain (CLBP), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Chronic Lower Back Pain (CLBP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Lower Back Pain (CLBP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Lower Back Pain (CLBP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Lower Back Pain (CLBP) market

Report Highlights

  • In the coming years, Chronic Lower Back Pain (CLBP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain (CLBP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Lower Back Pain (CLBP). Launch of emerging therapies will significantly impact the Chronic Lower Back Pain (CLBP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Lower Back Pain (CLBP)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Lower Back Pain (CLBP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Lower Back Pain (CLBP) Pipeline Analysis
  • Chronic Lower Back Pain (CLBP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Lower Back Pain (CLBP) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic Lower Back Pain (CLBP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Lower Back Pain (CLBP) Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Chronic Lower Back Pain (CLBP) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Chronic Lower Back Pain (CLBP) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Lower Back Pain (CLBP) market size during the forecast period (2019-2032)?
  • At what CAGR, the Chronic Lower Back Pain (CLBP) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Chronic Lower Back Pain (CLBP) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Chronic Lower Back Pain (CLBP) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Chronic Lower Back Pain (CLBP)?
  • What is the historical Chronic Lower Back Pain (CLBP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Lower Back Pain (CLBP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Lower Back Pain (CLBP)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chronic Lower Back Pain (CLBP) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Chronic Lower Back Pain (CLBP) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Lower Back Pain (CLBP) in the USA, Europe, and Japan?
  • What are the Chronic Lower Back Pain (CLBP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Lower Back Pain (CLBP)?
  • How many therapies are developed by each company for Chronic Lower Back Pain (CLBP) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Chronic Lower Back Pain (CLBP) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Chronic Lower Back Pain (CLBP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Lower Back Pain (CLBP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Lower Back Pain (CLBP)?
  • What are the global historical and forecasted market of Chronic Lower Back Pain (CLBP)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Lower Back Pain (CLBP) market
  • To understand the future market competition in the Chronic Lower Back Pain (CLBP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Lower Back Pain (CLBP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Lower Back Pain (CLBP) market
  • To understand the future market competition in the Chronic Lower Back Pain (CLBP) market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allodynic Therapeutics
  • Braeburn Inc.
  • DiscGenics Inc.
  • Frontier Biotechnologies
  • Persica Pharmaceuticals
  • Scilex Holding

1 Key Insights2 Report Introduction
3 Chronic Lower Back Pain Market Overview at a Glance
3.1 Market Share (%) of Chronic Lower Back Pain by Therapies in 2019
3.2 Market Share (%) of Chronic Lower Back Pain by Therapies in 2032
4 Executive Summary of Chronic lower back pain (CLBP)5 Key Events
6 Chronic Lower Back Pain (CLBP): Disease Background and Overview
6.1 Introduction
6.2 Signs and Symptoms
6.3 Causes and Risk Factors
6.4 Genetics of Chronic Lower Back Pain
6.5 Pathophysiology
6.6 Types of pain
6.7 Diagnosis
6.7.1 Test for CLAB diagnosis
6.7.2 Imaging guidelines
6.8 Treatment and Management
6.8.1 Treatment Approaches
6.8.2 Treatment Algorithm
6.8.3 Proposed Guidelines for Chronic Lower Back Pain
6.8.3.1 NICE Guidelines
6.8.3.2 Center for Disease Control and Prevention (CDC) Guidelines
6.8.3.3 American College of Physicians (ACP) Guidelines
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Methodology
7.3 Total Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.4 Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM
7.5 The United States
7.5.1 Assumptions and Rationale
7.5.2 Total Prevalent Population of Chronic Lower Back Pain in the United States
7.5.3 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States
7.5.4 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.5.5 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
7.6 EU5
7.6.1 Assumptions and Rationale
7.6.2 Total Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.3 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5
7.6.4 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.6.5 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5
7.7 Japan
7.7.1 Assumptions and Rationale
7.7.2 Total Prevalent Population of Chronic Lower Back Pain in Japan
7.7.3 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan
7.7.4 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
7.7.5 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
8 Patient Journey
9 Marketed Therapies
9.1 Key Cross Competition
9.2 Cymbalta (Duloxetine): Eli Lilly and Company
9.2.1 Product Description
9.2.2 Regulatory Milestones
9.2.3 Other Developmental Activities
9.2.4 Clinical development
9.2.5 Clinical Trials Information
9.2.6 Safety and Efficacy
9.2.7 Product Profile
9.3 Xtampza: Collegium Pharmaceutical
9.3.1 Product Description
9.3.2 Regulatory Milestones
9.3.3 Other Developmental Activities
9.3.4 Clinical Development
9.3.5 Clinical trial information
9.3.6 Safety and Efficacy
9.3.7 Product Profile
9.4 Hysingla ER: Purdue Pharma LP
9.4.1 Product Description
9.4.2 Regulatory Milestones
9.4.3 Other Developmental Activities
9.4.4 Clinical Development
9.4.5 Clinical trial information
9.4.6 Safety and Efficacy
9.4.7 Product Profile
9.5 Butrans (buprenorphine): Purdue Pharma
9.5.1 Product Description
9.5.2 Regulatory Milestones
9.5.3 Clinical Development
9.5.4 Clinical Trials Information
9.5.5 Safety and Efficacy
9.5.6 Product Profile
9.6 Belbuca: BioDelivery Sciences International
9.6.1 Product Description
9.6.2 Regulatory Milestones
9.6.3 Other Developmental activities
9.6.4 Clinical Development
9.6.5 Clinical Trials Information
9.6.6 Safety and Efficacy
9.6.7 Product Profile
10 Emerging Therapies
10.1 Key Cross Competition
10.2 Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
10.2.1 Drug Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.2.7 Analysts’ Views
10.3 Semdexa (SP-102): Scilex Holding
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.4 Clinical Trials Information
10.3.5 Safety and Efficacy
10.3.6 Product Profile
10.3.7 Analysts’ Views
10.4 Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
10.4.1 Drug Description
10.4.2 Other Developmental Activities
10.4.3 Clinical Development
10.4.4 Clinical Trials Information
10.4.5 Safety and Efficacy
10.4.6 Product Profile
10.4.7 Analysts’ Views
10.5 AMG0103: AnGes MG, Inc.
10.5.1 Drug Description
10.5.2 Clinical Development
10.5.3 Clinical Trials Information
10.5.4 Safety and Efficacy
10.5.5 Product Profile
10.5.6 Analysts’ Views
10.6 KLS-2031: Kolon Life Science
10.6.1 Drug Description
10.6.2 Other Developmental Activities
10.6.3 Clinical Development
10.6.4 Clinical Trials Information
10.6.5 Product Profile
10.6.6 Analysts’ Views
10.7 ETX-810: Eliem Therapeutics
10.7.1 Drug Description
10.7.2 Other Developmental Activities
10.7.3 Clinical Development
10.7.4 Clinical Trials Information
10.7.5 Product Profile
10.7.6 Analysts’ Views
10.8 ALLOD-2: Allodynic Therapeutics
10.8.1 Product Description
10.8.2 Other Developmental Activities
10.8.3 Clinical Development
10.8.4 Clinical Trials Information
10.8.5 Product Profile
10.9 FB3001: Frontier Biotechnologies
10.9.1 Drug Description
10.9.2 Other Developmental Activities
10.9.3 Clinical Development
10.9.4 Clinical Trial Information
10.9.5 Safety and efficacy
10.9.6 Product profile
10.1 IDCT (rebonuputemcel): DiscGenics Inc.
10.10.1 Drug Description
10.10.2 Other Developmental Activities
10.10.3 Clinical Developmental Activities
10.10.4 Clinical trial information
10.10.5 Safety and efficacy
10.10.6 Product Profile
10.10.7 Analysts’ Views
10.11 SX600: SpineThera
10.11.1 Product Description
10.11.2 Other Developmental Activities
10.11.3 Clinical Development
10.11.4 Clinical Trials Information
10.11.5 Product Profile
10.12 STA363: Stayble Therapeutics
10.12.1 Product Description
10.12.2 Other Developmental Activities
10.12.3 Clinical Development
10.12.4 Clinical Trials Information
10.12.5 Product Profile
10.13 Clonidine Micropellets (STX-015): Sollis Therapeutics/Medtronic Spinal and Biologics
10.13.1 Product Description
10.13.2 Other Development Activities
10.13.3 Clinical development
10.13.4 Clinical Trials Information
10.13.5 Safety and Efficacy
10.13.6 Product Profile
10.14 Tanezumab: Eli Lilly/Pfizer
10.14.1 Product Description
10.14.2 Other Developmental Activities
10.14.3 Clinical Development
10.14.4 Clinical Trials Information
10.14.5 Safety and Efficacy
10.14.6 Product Profile
10.14.7 Analysts’ Views
10.15 LY3556050: Eli Lilly and Company
10.15.1 Drug Description
10.15.2 Clinical Development
10.15.3 Clinical Trials Information
10.15.4 Product Profile
10.16 PP353: Persica Pharmaceuticals
10.16.1 Drug Description
10.16.2 Other Developmental Activities
10.16.3 Clinical Development
10.16.4 Clinical Trials Information
10.16.5 Product Profile
10.17 BRTX-100: BioRestorative Therapies
10.17.1 Drug Description
10.17.2 Other Developmental Activities
10.17.3 Clinical Development
10.17.4 Clinical Trials Information
10.17.5 Product Profile
10.17.6 Analysts’ Views
10.18 VER-01: Vertanical GmbH
10.18.1 Drug Description
10.18.2 Clinical Development
10.18.3 Clinical Trials Information
10.18.4 Product Profile
10.19 BM-MSC/ReSpine: Montpellier University Hospital
10.19.1 Product Description
10.19.2 Clinical development
10.19.3 Clinical Trials Information
10.19.4 Product Profile
11 Failed therapies
11.1 Fasinumab (REGN475): Regeneron Pharmaceuticals/Teva Pharmaceuticals
11.1.1 Product Description
11.1.2 Other Developmental Activities
11.1.3 Clinical Development
11.1.4 Clinical Trials Information
11.1.5 Safety and Efficacy
11.1.6 Product Profile
12 Chronic Lower Back Pain: Seven Major Market Analysis
12.1 Key Findings
12.2 Market Methodology
12.3 Market Outlook
12.3.1 United States
12.3.2 EU-5 countries
12.3.3 Japan Market
12.4 Attribute Analysis
12.5 Potential of Emerging Therapies of Chronic Low Back Pain
12.6 Key Market Forecast Assumptions
12.7 Market size of Chronic Lower Back Pain in the 7MM
12.8 Market size of Chronic Lower Back Pain by Therapies in the 7MM
12.9 Market size of Chronic Lower Back Pain in the United States
12.9.1 Total Market size of Chronic Lower Back Pain in the United States
12.9.2 Market Size by Therapies in the US
12.1 Market size of Chronic Lower Back Pain in EU-5
12.10.1 Total Market size of Chronic Lower Back Pain in EU5
12.10.2 Market Size of Chronic Lower Back Pain in EU5 by Therapies
12.11 Market size of Chronic Lower Back Pain in Japan
12.11.1 Total Market size of Chronic Lower Back Pain
12.11.2 Market Size by Therapies in Japan
13 KOL Views14 Market Drivers15 Market Barriers16 SWOT Analysis17 Unmet Needs18 Market Access and Reimbursement
19 Appendix
19.1 Report Methodology
19.2 Bibliography
20 Capabilities21 Disclaimer22 About the Publisher
List of Tables
Table 1 Summary of CLBP Market and Epidemiology (2019-2032)
Table 2 Key Events
Table 3 Risk Factors for Occurrence and Chronicity of Low Back Pain
Table 4 Cause of Muscle Connective Tissue Fibrosis
Table 5 Clinical Evaluation
Table 6 Graded Chronic Pain Scale (GCPS)
Table 7 Summary of the Efficacy of Physical Treatments for Chronic LBP
Table 8 The American College of Physicians Guideline Grading System
Table 9 Clinical Practice Guideline From the American College of Physicians
Table 10 Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019-2032)
Table 11 Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019-2032)
Table 12 Total Prevalent Population of Chronic Lower Back Pain in the United States (2019-2032)
Table 13 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019-2032)
Table 14 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019-2032)
Table 15 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019-2032)
Table 16 Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019-2032)
Table 17 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5 (2019-2032)
Table 18 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019-2032)
Table 19 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU5 (2019-2032)
Table 20 Total Prevalent Population of Chronic Lower Back Pain in Japan (2019-2032)
Table 21 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019-2032)
Table 22 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019-2032)
Table 23 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019-2032)
Table 24 Key Cross of Approved Drugs
Table 25 Cymbalta, Clinical Trial Description, 2021
Table 26 Xtampza ER, Clinical Trial Description, 2021
Table 27 Hysingla ER, Clinical Trial Description, 2021
Table 28 Butrans, Clinical Trial Description, 2021
Table 29 Belbuca, Clinical Trial Description, 2021
Table 30 Comparison of emerging drugs under development
Table 31 Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Clinical Trial Description, 2021
Table 32 Semdexa (SP-102), Clinical Trial Description, 2021
Table 33 Rexlemestrocel-L, Clinical Trial Description, 2021
Table 34 AMG0103, Clinical Trial Description, 2021
Table 35 KLS-2031, Clinical Trial Description, 2021
Table 36 ETX-810, Clinical Trial Description, 2021
Table 37 ALLOD-2, Clinical Trial Description, 2021
Table 38 FB3001, Clinical Trial Description, 2021
Table 39 IDCT, Clinical Trial Description, 2021
Table 40 SX600, Clinical Trial Description, 2021
Table 41 STA363, Clinical Trial Description, 2021
Table 42 Clonidine Micropellets, Clinical Trial Description, 2021
Table 43 Tanezumab, Clinical Trial Description 2021
Table 44 LY3556050 Clinical Trial Description, 2021
Table 45 PP353 Clinical Trial Description, 2021
Table 46 BRTX-100, Clinical Trial Description, 2021
Table 47 VER-01, Clinical Trial Description, 2021
Table 48 BM-MSC, Clinical Trial Description, 2021
Table 49 Fasinumab, Clinical Trial Description, 2021
Table 50 Key Market Forecast Assumptions for Brixadi
Table 51 Key Market Forecast Assumptions for Rexlemestrocel-L
Table 52 Key Market Forecast Assumptions for SEMDEXA/SP-102
Table 53 Key Market Forecast Assumptions for Clonidine Micropellets (STX-015)
Table 54 Key Market Forecast Assumptions for Tanezumab
Table 55 Seven Major Market Size of Chronic Lower Back Pain in USD Million (2019-2032)
Table 56 Market Size of Chronic Low Back Pain by therapies in the 7MM, in USD Million (2019-2032)
Table 57 United States Market Size of Chronic Lower Back Pain in USD Million (2019-2032)
Table 58 Market Size of Chronic Low Back Pain by therapies in the US in USD Million (2019-2032)
Table 59 EU-5 Market Size of Chronic Lower Back Pain in USD Million (2019-2032)
Table 60 Market Size of Chronic Low Back Pain by therapies in EU-5 in USD Million (2019-2032)
Table 61 Market Size of Chronic Lower Back Pain in Japan, in USD Million (2019-2032)
Table 62 Market Size of Chronic Low Back Pain by therapies in Japan in USD Million (2019-2032)
List of Figures
Figure 1 Types of Lower Back Pain
Figure 2 Definitions of Chronic Lower Back Pain
Figure 3 Signs and Symptoms of CLBP
Figure 4 Pathophysiological Model for Chronic Low Back Pain Linking Somatic and Behavioral Components
Figure 5 Relationship Describing Therapeutic Inventions and Pathogenic Mechanism
Figure 6 Types of Pain Involved in CLBP mechanism
Figure 7 The Vicious Circle showing the Interaction Of Influencing Factors
Figure 8 Treatment Algorithm for Chronic Low Back Pain
Figure 9 Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019-2032)
Figure 10 Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019-2032)
Figure 11 Total Prevalent Population of Chronic Lower Back Pain in the United States (2019-2032)
Figure 12 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019-2032)
Figure 13 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019-2032)
Figure 14 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019-2032)
Figure 15 Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019-2032)
Figure 16 Total Diagnosed Prevalent Population of CLBP in EU-5 (2019-2032)
Figure 17 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019-2032)
Figure 18 Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019-2032)
Figure 19 Total Prevalent Population of Chronic Lower Back Pain in Japan (2019-2032)
Figure 20 Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019-2032)
Figure 21 Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019-2032)
Figure 22 Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019-2032)
Figure 23 Market Size of Chronic Lower Back Pain in the 7MM, USD Millions (2019-2032)
Figure 24 Market Size of Chronic Lower Back Pain by Therapies in the 7MM, USD Millions (2019-2032)
Figure 25 Market Size of Chronic Lower Back Pain in the United States, USD Millions (2019-2032)
Figure 26 Market size of CLBP by therapies in the United States, in USD Million (2019-2032)
Figure 27 Total Market Size of Chronic Lower Back Pain in EU5, USD Millions (2019-2032)
Figure 28 Market Size of Chronic Low Back Pain by therapies in EU-5, in USD Million (2019-2032)
Figure 29 Market Size of Chronic Lower Back Pain in Japan, USD Millions (2019-2032)
Figure 30 Market Size of Chronic Low Back Pain by therapies in Japan, in USD Million (2019-2032)
Figure 31 Market Drivers
Figure 32 Market Barriers
Figure 33 Unmet Needs
Figure 34 SWOT Analysis
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Eli Lilly and Company
  • Collegium Pharmaceutical
  • Purdue Pharma LP
  • BioDelivery Sciences International
  • Camurus
  • Braeburn Inc.
  • Scilex Holding
  • Mesoblast Limited
  • AnGes MG, Inc.
  • Kolon Life Science
  • Eliem Therapeutics
  • Allodynic Therapeutics
  • Sollis Therapeutics
  • Medtronic Spinal and Biologics
  • Frontier Biotechnologies
  • DiscGenics Inc.
  • Pfizer
  • Persica Pharmaceuticals
  • BioRestorative Therapies
  • Vertanical GmbH
  • Stayble Therapeutics
  • SpineThera
Note: Product cover images may vary from those shown